Valneva SE

Valneva Announces the Availability of Documentation for its Shareholder Meetings

02 Jun 2022 13:50:00 By Nasdaq GlobeNewswire

Valneva Appoints Dr. Thomas Decker and Dr. Michael Pfleiderer to its Scientific Advisory Board

31 May 2022 10:45:00 By Nasdaq GlobeNewswire

Valneva Successfully Completes Lot-to-Lot Consistency Trial for its Single-Shot Chikungunya Vaccine Candidate

25 May 2022 00:00:00 By Nasdaq GlobeNewswire

EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

19 May 2022 00:00:00 By Nasdaq GlobeNewswire

Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

16 May 2022 00:15:00 By Nasdaq GlobeNewswire

Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

16 May 2022 00:00:00 By Nasdaq GlobeNewswire

Valneva Reports Q1 2022 Results and Provides Corporate Updates

05 May 2022 00:00:00 By Nasdaq GlobeNewswire

Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine Candidate

04 May 2022 10:45:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - April 30, 2022

03 May 2022 11:00:00 By Nasdaq GlobeNewswire

Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate

26 Apr 2022 00:00:00 By Nasdaq GlobeNewswire